|
[1]WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroenterology, 2004, 126 (7) :1750-1758.
|
|
[2]BUSCA A, KUMAR A.Innate immune responses in hepatitis B virus (HBV) infection[J].Virol J, 2014, 11:22.
|
|
[3]GLEBE D.Recent advances in hepatitis B virus research:a German point of view[J].World J Gastroenterol, 2007, 13 (1) :8-13.
|
|
[4]CHAN C, ABU-RADDAD E, GOLOR G, et al.Clinical phamacokinetics of alamifovir and its metabolites[J].Antimicrob Agents Chemother, 2005, 49 (5) :1813-1822.
|
|
[5]BERTOLETTI A, FERRARI C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut, 2012, 61 (12) :1754-1764.
|
|
[6]MARCELLIN P, ASSELAH T.Long-term therapy for chronic hepatitis B:hepatitis B virus DNA suppression leading to cirrhosis reversal[J].J Gastroenterol Hepatol, 2013, 28 (6) :912-923.[7]Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].Clin J Viral Dis, 2011, 1 (1) :9-23. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010版) [J].中国病毒病杂志, 2011, 1 (1) :9-23.
|
|
[8]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.
|
|
[9]LIAW YF, KAO JH, PIRATVISUTH T, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J].Hepatol Int, 2012, 6 (3) :531-561.
|
|
[10] LOK AS, MCMAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology, 2009, 50 (3) :661-662.
|
|
[11]LOCARNINI S.Molecular virology of hepatitis B virus[J].Semin Liver Dis, 2004, 24 (Suppl 1) :3-10.
|
|
[12]LEVRERO M, POLLICINO T, PETERSEN J, et al.Control of cccDNA function in hepatitis B virus infection[J].J Hepatol, 2009, 51 (3) :581-592.
|
|
[13]WEI Y, NEUVEUT C, TIOLLAIS P, et al.Molecular biology of the hepatitis B virus and role of the X gene[J].Pathol Biol (Paris) , 2010, 58 (4) :267-272.
|
|
[14]ABU-AMARA M, FELD JJ.Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?[J].Semin Liver Dis, 2013, 33 (2) :157-166.
|
|
[15]WURSTHORN K, LUTGEHETMANN M, DANDRI M, et al.Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B[J].Hepatology, 2006, 44 (3) :675-684.
|
|
[16]ZOULIM F.Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection[J].Antiviral Res, 2004, 64 (1) :1-15.
|
|
[17]BALSANO C, ALISI A.Viral hepatitis B:established and emerging therapies[J].Curr Med Chem, 2008, 15 (9) :930-939.
|
|
[18]FUNG J, LAI CL, SETO WK, et al.Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B[J].J Antimicrob Chemother, 2011, 66 (12) :2715-2725.
|
|
[19]KAMIYA N.The mechanisms of action of antivials against hepatitis B virus infection[J].J Antimicrob Chemother, 2003, 51 (5) :1085-1089.
|
|
[20]GISH R, JIA JD, LOCARNINI S, et al.Selection of chronic hepatitis B therapy with high barrier to resistance[J].Lancet Infect Dis, 2012, 12 (4) :341-353.
|
|
[21]REIJNDERS JG, JANSSEN HL.Relapse of chronic hepatitis B after discontinuation of nucleos (t) ide analogs:is the glass half full or half empty?[J].Hepatology, 2013, 58 (6) :1885-1887.
|
|
[22]CHANG TT, LIAW YF, WU SS, et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology, 2010, 52 (3) :886-893.
|
|
[23]MARINOS G, NAOUMOV NV, WILLIAMS R.Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection[J].Hepatology, 1996, 24 (5) :991-995.
|
|
[24]BONI C, BERTOLATTI A, PENNA A, et al.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B[J].J Clin Invest, 1998, 102 (5) :968-975.
|
|
[25]BONI C, PENNA A, OGG GS, et al.Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy[J].Hepatology, 2001, 33 (4) :963-971.
|
|
[26]EVANS A, RIVA A, COOKSLEY H, et al.Programmed death 1expression during antiviral treatment of chronic hepatitis B:impact of hepatitis B e-antigen seroconversion[J].Hepatology, 2008, 48 (3) :759-769.
|
|
[27]ZHANG JY, SONG CH, SHI F, et al.Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment[J].PLoS One, 2010, 5 (11) :e13869.
|
|
[28]YEH CT, HSU CW, CHEN YC, et al.Withdrawal of lamivudine in HBeAg positive chronic hepatitis B patients after achieving effective maintained virological suppression[J].J Clin Virol, 2009, 45 (2) :114-118.
|
|
[29]LIAW YF, LEUNG N, KAO JH, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update[J].Hepatol Int, 2008, 2 (3) :263-283.
|
|
[30]LEE HW, LEE HJ, HWANG JS, et al.Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B[J].Hepatology, 2010, 51 (2) :415-421.
|
|
[31]LOK AS, MCMAHON BJ.Chronic hepatitis B:update of recommendations[J].Hepatology, 2004, 39 (3) :857-861.
|
|
[32]LIANG Y, JIANG J, SU M, et al.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy[J].Aliment Pharmacol Ther, 2011, 34 (3) :344-352.
|
|
[33]PAN XF, ZHANG K, YANG XA, et al.Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients[J].PLoS One, 2013, 8 (7) :e68568.
|
|
[34]LIAW YF, LEUNG N, GUAN R, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2005 update[J].Liver Int, 2005, 25 (3) :472-489.
|
|
[35]JIANG JN, HUANG ZL, HE LX, et al.Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos (t) ide analogs[J].J Clin Gastroenterol, 2014.[Epub ahead of print]
|
|
[36]JENG WJ, SHEEN IS, CHEN YC, et al.Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients[J].Hepatology, 2013, 58 (6) :1888-1896.
|
|
[37]SETO WK, HUI AJ, WONG WS, et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study[J].Gut, 2014.[Epub ahead of print]
|
|
[38]SONG BC, SUH DJ, LEE HC, et al.Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea[J].Hepatology, 2000, 32 (4 Pt 1) :803-806.
|
|
[39]REIJNDERS JG, PERQUIN MJ, ZHANG NP, et al.Nucleos (t) ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J].Gastroenterology, 2010, 139 (2) :491-498.
|
|
[40]FUNG SK, WONG F, HUSSAIN M, et al.Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B[J].J Viral Hepat, 2004, 11 (5) :432-438.
|
|
[41]CHAN HL, WANG H, NIU J, et al.Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B:a double-blind, placebo-controlled trial[J].Antivir Ther, 2007, 12 (3) :345-353.
|
|
[42]HADZIYANNIS SJ, SEVASTIANOS V, RAPTI I, et al.Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J].Gastroenterology, 2012, 143 (3) :629-636.
|
|
[43]LIU F, WANG L, LI XY, et al.Poor durability of lamivudine effectiveness despite stringent cessation criteria:a prospective clinical
|
|
[]study in hepatitis B e antigen-negative chronic hepatitis B patients[J].J Gastroenterol Hepatol, 2011, 26 (3) :456-460.
|
|
[44]DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ, et al.Histological outcome during long-term lamivudine therapy[J].Gastroenterology, 2003, 124 (1) :105-117.
|
|
[45]XU B, LIN LY, XU GG, et al.Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B[J].J Gastroenter Hepatol, 2014.[Epub ahead of print]
|
|
[46]HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ, et al.Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B for up to 5 years[J].Gastroenterology, 2006, 131 (6) :1743-1751.
|
|
[47]MARCELLIN P, CHANG TT, LIM SG, et al.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology, 2008, 48 (3) :750-758.
|
|
[48]LIAW YF.Reversal of cirrhosis:an achievable goal of hepatitis B antiviral therapy[J].J Hepatol, 2013, 59 (4) :880-881.
|
|
[49]SCHIFF ER, LEE SS, CHAO YC, et al.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J].Clin Gastroenterol Hepatol, 2011, 9 (3) :274-276
|
|
[50]LIAW YF, RAPTOPOULOU-GIGI M, CHEINQUER H, et al.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompesation:a randomized, open-label study[J].Hepatology, 2011, 54 (1) :91-100.
|
|
[51]LIAW YF, SHEEN IS, LEE CM, et al.Tenofovir disoproxil fumarate (TDF) , emtricitabine/TDF, and entecavir in patients with decompesated chronic hepatitis B liver disease[J].Hepatology, 2011, 53 (1) :62-72.
|
|
[52]YUEN MF, SETO WK, CHOW DH, et al.Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease[J].Antivir Ther, 2007, 12 (8) :1295-1303.
|
|
[53]LIAW YF, SUNG JJ, CHOW WC, et al.The CALM Study Group.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531.
|
|
[54]MATSUMOTO A, TANAKA E, ROKUHARA A, et al.The Inuyama Hepatitis Study Group.Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:a multicenter retrospective study of 2795 patients[J].Hepatol Res, 2005, 32 (3) :173-184.
|
|
[55]DI MARCO V, MARZANO A, LAMPERTICO P, et al.Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy.Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine[J].Hepatology, 2004, 40 (4) :883-891.
|
|
[56]SUNG JJ, TSOI KK, WONG VW, et al.Meta-analysis:treatment of hepatitis B infection reduces risk of hepatocellular carcinoma[J].Aliment Pharmacol Ther, 2008, 28 (9) :1067-1077.
|
|
[57]PAPATHEODORIDIS GV, LAMPERTICO P, MANOLAKOPOULOS S, et al.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy:a systematic review[J].J Hepatol, 2010, 53 (2) :348-356.
|
|
[58]EUN JR, LEE HJ, KIM TN, et al.Risk assessment for the development of hepatocellular carcinoma:according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease[J].J Hepatol, 2010, 53 (1) :118-125.
|
|
[59]SU TH, HU TH, LIN CC, et al.Reduction of hepatocellular carcinoma in hepatitis B related cirrhosis patients with long-term entecavir therapy-an interim report of C-TEAM study[J].Hepatology, 2013, 58 (Suppl 1) :301a.
|
|
[60]WU CY, LIN JT, HO HJ, et al.Association of nucleos (t) ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-a nationwide cohort study[J].Gastroenterology, 2014, 147 (1) :143-151.
|
|
[61]KUMADA T, TOYODA H, TADA T, et al.Effect of nucleos (t) ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis[J].J Hepatology, 2013, 58 (3) :427-433.
|
|
[62]PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al.Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral (s) starting with lamivudine monotherapy:results of the nationwide HEPNET.Greece cohort study[J].Gut, 2011, 60 (8) :1109-1116.
|
|
[63]FATTOVICH G, BORTOLOTTI F, DONATO F.Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors[J].J Hepatology, 2008, 48 (2) :335-352.
|
|
[64]PAPATHEODORIDIS G, MANOLAKOPOULOS S, TOULOUMI G, et al.Hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-) with or without cirrhosis treated with entecavir:results of the nationwide HepNet Greece Cohort Study[J].J Hepatol, 2013, 58 (Suppl 1) :s312.
|
|
[65]LAMPERTICO P, SOFFREDINI R, YURDAYDIN C, et al.Four years of tenofovir monotherapy for NUC nave field practice European patients suppress HBV replication in most patients with a favourable renal safety profile but do not prevent HCC in patients with or without cirrhosis[J].Hepatology, 2013, 58 (Suppl 1) :653a.
|
|
[66]PAPATHEODORIDIS GV, DALEKOS GN, YURDAYDIN C, et al.Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF) [J].Hepatology, 2013, 58 (Suppl 1) :302a.
|
|
[67]CHO JY, PAIK YH, SOHN W, et al.Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease[J].Gut, 2014.[Epub ahead of print]
|
|
[68]LAMPERTICO P, SOFFREDINI R, VIGANO M, et al.5-year entecavir treatment in NUC-nave, field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhosis[J].J Hepatol, 2013, 58 (Suppl 1) :s306.
|
|
[69]HOSAKA T, SUZUKI F, KOBAYASHI M, et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J].Hepatology, 2013, 58 (1) :98-107.
|
|
[70]WONG GL, CHAN HL, CHAN HY, et al.Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment[J].Gastroenterology, 2013, 144 (5) :933-944.
|
|
[71]KIM WR, BERGT, LOOMB R, et al.Long-term tenofovir disoproxil fumarate therapy and the risk of hepatocellular carcinoma[J].J Hepatol, 2013, 58 (Suppl 1) :s19.
|
|
[72]HILLERET MN, LARRAT S, STANKE-LABESQUE F, et al.Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?[J].J Hepatol, 2011, 55 (6) :1468-1469.
|
|
[73]BERG T, MARCELLIN P, ZOULIM F, et al.Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic hepatitis B virus infection[J].Gastroenterology, 2010, 139 (4) :1207-1217.
|
|
[74]World Health Organization.Adherence to long-term therapies:evidence for action[EB/OL].[2014-08-12].http://www.who.int/chp/knowledge/publications/adherencefull_report.pdf.
|
|
[75]CHOTIYAPUTTA W, PETERSON C, DITAH FA, et al.Persistence and adherence to nucleos (t) ide analogue treatment for chronic hepatitis B[J].J Hepatol, 2011, 54 (1) :12-18.
|
|
[76]LEE M, KEEFFE EB.Study of adherence comes to the treatment of chronic hepatitis B[J].J Hepatol, 2011, 54 (1) :6-8.
|
|
[77]GIANG L, SELLINGER CP, LEE AU.Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires[J].World J Hepatol, 2012, 4 (2) :43-49.
|
|
[78]SUN MS, WANG GQ, ZHANG W, et al.The current status of lamivudine-treated patients with chronic hepatitis B[J].Chin Prevent Med, 2012, 13 (1) :18-22. (in Chinese) 孙秘书, 王贵强, 张伟, 等.拉米夫定经治慢性乙型肝炎患者治疗现状调查分析[J].中国预防医学杂志, 2012, 13 (1) :18-22.
|
|
[79]YE LH, HU ZQ, LI ZL.A study on compliance of chronic hepatits B patients with treatment[J].J Pract Hepatol, 2013, 16 (2) :155-156. (in Chinese) 叶丽华, 胡兆琴, 李正莲.慢性乙型肝炎患者诊断治疗依从性行为调查[J].实用肝脏病杂志, 2013, 16 (2) :155-156.
|
|
[80]AN P, BIAN L, YIN B, et al.Risk factors of gene-resistant mutations in different nucleosides[J].Hepato-Gastroenterology, 2012, 59 (113) :228-230.
|
|
[81]ZENG MD, MAO YM, YAO GB, et al.Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B[J].Liver Int, 2012, 32 (1) :137-146.
|
|
[82]SUN J, XIE Q, TAN DM, et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients:a randomized, controlled study[J].Hepatology, 2014, 59 (4) :1283-1292.
|
|
[83]Experts attending the discussion on hepatitis B virus drug resistance.Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management[J].Chin J Viral Dis, 2013, 3 (1) :1-11. (in Chinese) 参加乙型肝炎耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].中国病毒病杂志, 2013, 3 (1) :1-11.
|
|
[84]PIPILI C, CHOLONGITAS E, PAPATHEODORIDIS G.Review article:nucleos (t) ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].Aliment Pharmacol Ther, 2014, 39 (1) :35-46.
|
|
[85]JUNG YK, YEON JE, CHOI JH, et al.Fanconi’s syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient[J].Gut Liver, 2010, 4 (3) :389-393.
|
|
[86]VERHELST D, MONGE M, MEYNARD JL, et al.Fanconi syndrome and renal failure induced by tenofovir:a first case report[J].Am J Kidney Dis, 2002, 40 (6) :1331-1333.
|
|
[87]GASPAR G, MONEREO A, GARCA-REYNE A, et al.Fanconi syndrome and acute renal failure in a patient treated with tenofovir:a call for caution[J].AIDS, 2004, 18 (2) :351-352.
|
|
[88]POL S, LAMPERTICO P.First-line treatment of chronic hepatitis B with entecavir or tenofovir in real-life settings:from clinical trials to clinical practice[J].J Viral Hepat, 2012, 19 (6) :377-386.
|
|
[89]LIAW YF, GANE E, LEUNG N, et al.2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology, 2009, 136 (2) :486-495.
|
|
[90] LAI CL, GANE E, LIAW YF, et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med, 2007, 357 (25) :2576-2588.
|
|
[91]REN JB, WANG Y, LI HY, et al.Telbivudine-associated creatine kinase elevation in chronic hepatitis B patients[J].Chin J Hepatol, 2012, 20 (9) :641-643. (in Chinese) 任江波, 王宇, 李红艺, 等.替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析[J].中华肝脏病杂志, 2012, 20 (9) :641-643.
|
|
[92]CHAN HL, WONG VW, TSE AM, et al.Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J].Clin Gastroenterol Hepatol, 2007, 5 (12) :1462-1468.
|
|
[93]NING Q, HAN M, SUN Y, et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial (OSST trial) [J].J Hepatol, 2014.[Epub ahead of print]
|
|
[94]XIE Q, ZHOU HJ, BAI XF, et al.A Randomized, open-label clinical study of combined peginterferon alfa-2a (40KD) and entecavir treatment for HBeAg–positive chronic hepatitis B[J].Clin Infect Dis, 2014.[Epub ahead of print]
|
DownLoad: